AML and the art of remission maintenance.
Acute myeloid leukemia
Hematopoietic cell transplant
Intensive chemotherapy
Maintenance therapy
Remission
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
24
08
2020
revised:
18
03
2021
accepted:
22
03
2021
pubmed:
10
4
2021
medline:
18
11
2021
entrez:
9
4
2021
Statut:
ppublish
Résumé
Relapse in acute myeloid leukemia (AML) is common, especially in older patients, and there is currently no standard of care maintenance therapy for those who achieve complete remission. Finding effective, tolerable maintenance therapy to prolong remission has been a goal for decades, but early clinical trials testing a variety of agents demonstrated disappointing results with no overall survival benefit. CC-486, an oral hypomethylating agent, was recently approved in the United States for maintenance treatment in patients with AML in first remission following chemotherapy. A number of ongoing studies are assessing various therapeutics in the maintenance setting, including other hypomethylating agents, targeted small-molecule inhibitors, monoclonal antibodies, and immunomodulators. New strategies are needed to identify patients most likely to benefit from maintenance therapy, including those for whom a preemptive approach reliant on monitoring of measurable residual disease would be advantageous.
Identifiants
pubmed: 33832807
pii: S0268-960X(21)00035-7
doi: 10.1016/j.blre.2021.100829
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
cc-486
0
Azacitidine
M801H13NRU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100829Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.